|
Arthritis, Psoriatic
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis.
|
18752933 |
2009 |
|
Arthritis, Psoriatic
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Association of interleukin 23 receptor variants with psoriatic arthritis.
|
19040306 |
2009 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
More recently, analysis of psoriasis genome-wide association studies in a PsA subgroup has also implicated IL23A, TNFAIP3, and TNIP1 genetic variants as conferring risk to PsA.
|
20875338 |
2010 |
|
Arthritis, Psoriatic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis.
|
21623003 |
2011 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest a role of the IL-17/IL-23 cytokine axis in synovial LN in PsA.
|
22541888 |
2012 |
|
Arthritis, Psoriatic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We confirm the previously described association of rs2066808 variant with psoriasis and PsA and we show evidence of an extended genomic region inside IL23A gene as carrier of true disease susceptibility factors.
|
23673284 |
2013 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus.
|
24957500 |
2014 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Psoriatic arthritis (PsA) can be treated using biologic therapies targeting biomolecules such as tumor necrosis factor alpha, interleukins (IL)-17 and IL-23.
|
26108918 |
2016 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biological DMARDs (bDMARDs) targeting cytokines IL-12/IL-23, TNF and IL-17 involved in the pathogenesis of PsA, have been emerging for the treatment.
|
27586804 |
2016 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IL-23/IL-17 axis plays a critical pathogenic role for both PsA and Ps, and biologics neutralizing IL-17A or IL-23/IL-12 are effective therapies for PsA and Ps.
|
27666819 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cytokines interleukin (IL)-12 and IL-23 have been involved in the pathogenesis of psoriasis and psoriatic arthritis.
|
28441904 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, polymorphisms of <i>IL23R</i> are a risk factor for ankylosing spondylitis (AS) and psoriatic arthritis (PsA), which indicates that IL-23 is also involved in the pathogenesis of spondyloarthritis (SpA).
|
28850053 |
2017 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IL-23/IL-17 axis is central to the pathogenesis of psoriatic arthritis (PsA).
|
29148410 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IL-23/Th17 axis has been implicated in the development of autoimmune diseases, such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
|
29148561 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study we show that psoriatic arthritis (PsA), a severe disease of the joints depending on the activation of the IL-23/IL-17 pathway, is characterized by a skewed ILC homeostasis.
|
29330320 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Perturbation of the IL-23/Th17 axis instigates Th17-mediated inflammation in R26Stat3C<sup>stopfl/fl</sup> CD4Cre mice, leading to cutaneous and synovio-entheseal inflammation and bone pathologic features highly reminiscent of human PsA.
|
29439292 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.
|
30172115 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we will discuss recent advances on the cellular and molecular pathophysiological mechanisms that regulate the initiation and progression of PsA as well as new therapeutic approaches for IL-23/IL-23R targeted therapeutics.
|
30196070 |
2019 |
|
Arthritis, Psoriatic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the study, a higher level of IL-17 and IL-23 was also shown in patients with psoriatic arthritis in comparison to patients with normal psoriasis.
|
30206447 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The unique bone phenotype that occurs in PsA and AS is a surprising coexistence of both systemic bone loss and periosteal and entheseal bone formation and is likely to be the result of the actions of IL-23 and/or IL-17 on bone.
|
30266977 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association to PsA was observed in the presence of polymorphisms: TNF-238 G > A (rs361525), -308 G > A (rs1800629), and -857 C > T (rs1799724); IL12B C > G (rs6887695) and A > C (rs3212227); IL23A A > G (rs2066808) and IL23R G > A (rs11209026).
|
30584776 |
2019 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome.
|
30858782 |
2019 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical trials have reported the effectiveness of numerous biologics with different targets, such as tumor necrosis factor-α, interleukin (IL)-17A, IL-17 receptor, IL-12/23(p40), and IL-23(p19) for the treatment of PsA.
|
30891646 |
2019 |
|
Arthritis, Psoriatic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In comparison with PsA, AA was associated with higher levels of IL-17F, IL-17E and IL-23.
|
30980732 |
2020 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-17A (IL-17A), IL-17F, IL-23, and CRP concentrations were measured in serum samples collected as part of the 2 PSUMMIT phase III studies of ustekinumab in PsA (n = 927).
|
31070869 |
2019 |